Hubei Vanz Pharm Co.,ltd
Hubei Vanz Pharm Co.,ltd

Warrantable quality,Trustable service!

Home ProductsActive Pharmaceutical Ingredient

75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals

75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals

  • 75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals
  • 75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals
  • 75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals
75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals
Product Details:
Place of Origin: CHINA(MAINLAND)
Brand Name: VANZ
Certification: COA
Payment & Shipping Terms:
Minimum Order Quantity: 10g
Packaging Details: in aluminium or on clients requirements
Delivery Time: 3days after paid
Payment Terms: T/T, Western Union, MoneyGram
Contact Now
Detailed Product Description
Appearance: White Crystal Powder Other Name: LEFLUNOMIDE
MF: C12H9F3N2O2 MW: 270.2
Melting Point: 165-166°C CAS NO.: 75706-12-6
High Light:

Pharma Raw Materials


medicine raw material

75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals
Product details:


Leflunomide is Raw Material for immunosuppressive disease-modifying antirheumatic drug (DMARD),used in active moderate to severe rheumatoid arthritis and psoriatic arthritis.

  • High quality raw material Leflunomide

    Common Name: Leflunomide
    Category: Pharmaceutical meterial
    Chemical Name: 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazole carboxamide
    M.F.: C12H9F3N2O2
    M.W.: 270.21
    Packing: 1kg/5kg in aluminium tin . 20kg in cardboard drum.
    CAS No.: 75706-12-6
    Quality Standard:
    Item Requirement Result
    Description White crystals powder White crystals powder
    Melting point 165-166°C 165-166°C
    Identification IR Identical
    Assay ≥99% 99.5%
    Heavy metal ≤10ppm ≤10ppm
    Loss on drying ≤1.0% ≤1.0%
    Ask ≤0.1%






​Leflunomide is an immunosuppressive drug that inhibits T and B cell responses. Leflunomide is an inhibitor of Cox-2, of tyrosine phosphorylation (tyrosine kinase), of DHODH (dihydroorotate dehydrogenase), an enzyme for de novopyrimidine synthesis, and of TNF-dependent NF-κB activation. The physiological activity of leflunomide is attributed mainly to its metabolite A77 1726.



Mechanism of Action:

Leflunomide is an immunomodulatory drug that achieves its effects by inhibiting the mitochondrial enzymedihydroorotate dehydrogenase (DHODH), which plays a key role in the de novo synthesis of uridine monophosphate(rUMP), which is required for the synthesis of DNA and RNA. Hence, leflunomide inhibits the reproduction of rapidly dividing cells, especially lymphocytes.
The inhibition of human DHODH by teriflunomide, the active metabolite of leflunomide, occurs at levels (approximately 600 nM) that are achieved during treatment of rheumatoid arthritis (RA).Teriflunomide also inhibits several tyrosine kinases.Teriflunomide prevents the expansion of activated and autoimmune lymphocytes by interfering with their cell cycle progression while nonlymphoid cells are able to use another pathway to make their ribonucleotides by use of salvage pyrimidine pathway, which makes them less dependent onde novo synthesis.Teriflunomide also has antiviral effects against numerous viruses including CMV, HSV1 and the BK virus, which it achieves by inhibiting viral replication by interfering with nucleocapsid tegumentation and hence virion assembly.


Side Effects:


Its principle dose-limiting side effects are liver damage, lung disease and immunosuppression.The most common side effects (occurring in >1% of those treated with it) are, in approximately descending order of frequency: diarrhea, respiratory tract infections, hair loss, high blood pressure, rash, nausea, bronchitis, headache, abdominal pain, abnormal liver function tests, back pain,indigestion, urinary tract infection, dizziness, infection, joint disorder, itchiness, weight loss, loss of appetite, cough, gastroenteritis, pharyngitis, stomatitis, tenosynovitis, vomiting, weakness, allergic reaction, chest pain, dry skin, eczema,paraesthesia, pneumonia, rhinitis, synovitis, cholelithiasis andshortness of breath.


Related products:


Glimepiride cas no.93479-97-1
Epalrestat cas  no.82159-09-9
Nateglinide cas no.105816-04-4
Risedronate sodium cas no.115436-72-1
zoledronic acid cas no.165800-06-6
Leflunomide cas no.75706-12-6
liranaftate cas no.88678-31-3
febuxostat cas no.144060-53-7
agomelatine cas no.38112-76-2


Packaging & Shipping

1kg/Aluminum foil bag
1kg/ Aluminium Tin
25kg/ Aluminum Drum
Delivery Time:

Usually within 3 working days after confirming the payment.
Company's info


75706-12-6 Leflunomide Medicine Raw Materials For Pharmaceuticals 0

Contact Details
Hubei Vanz Pharm Co.,ltd

Contact Person: Ms. Wendy Wang

Tel: +86 15927784577

Fax: 86-27-84492310

Send your inquiry directly to us
Hubei Vanz Pharm Co.,ltd
Room 2114, Jingkai future town, Longyang Road, Wuhan Economic & Technological Development District, Wuhan City, Hubei , China
Mobile Site Privacy PolicyChina active pharmaceuticals ingredients Supplier. Copyright © 2016 - 2022 All Rights Reserved. Developed by ECER